Veröffentlichungen 2000


1. Brix G, Henze M, Doll J, Lucht R, Zaers J, Trojan H, Knopp MV, Haberkorn U. Diagnostik evaluation of the breast using PET: Optimization of data acquisition and postprocessing. Nuklearmed 2000;39:62-66.

2. Clorius JH, Schottler T, Haufe S, Zuna I, Reinbold F, Kaick G van. Afferent-efferent vessel dysfunction appears to be a specific characteristic of a large subset of patients with essential hypertension. American Journal of Hypertension 2000;13:332-339.

3. Deigner HP, Haberkorn U, Kinscherf R. Apoptosis modulators in the therapy of neurodegenerative diseases. Exp Opin Invest Drugs 2000;9:747-764.

4. Dimitrakopoulou­-Strauss A, Strauss LG, Gutzler F, Rudi J. Parametric PET imaging in patients with hepatocellular carcinomas scheduled for percutaneous ethanol injection: Current and potential applications of C­11­Ethanol. Medical Imaging International 2000;10:6-11.

5. Eisenhut M, Haberkorn U. (123I)VIP receptor scintigraphy in patients with pancreatic adenocarcinomas. Eur J Nucl Med 2000;27:1589-1590.

6. Eisenhut M, Hull WH, Mohammed A, Mier W, Lay D, Just W, Gorgas K, Lehmann WD, Haberkorn U. Radioiodinated N-(2-Diethylaminoethyl)benzamide Derivatives with High Melanoma Uptake; Structure-Affinity Relationship Studies, Metabolic Fate and Intracellular Localisation J Med Chem 2000;43:3913-3922.

7. Haberkorn U. Neuentwicklungen und Perspektiven der PET. I Apoptose, Peptide, Gentherapie. Der Nuklearmediziner 2000;23:219-229.

8. Kahle B, Hoffend J, Hartschuh W, Petzoldt D. Ultrasound imaging of the sentinel lymph node in malignant melanoma. Hautarzt 2000;51:915-9.

9. Mier W, Eritja R, Mohammed A, Haberkorn U, Eisenhut M. Preparation and Evaluation of Tumor-Targeting Peptide-Oligonucleotide Conjugates. Bioconjugate Chemistry 2000;11:855-860.

10. Rohrschneider WK, Hoffend J, Becker K, Clorius JH, Darge K, Kooijman H, Troeger J. Combined static-dynamic MR urography for the simultaneous evaluation of morphology and function in urinary tract obstruction. I. Evaluation of the normal status in an animal model. Pediatr Radiol 2000;30(8):511-22.

11. Rohrschneider WK, Becker K, Hoffend J, Clorius JH, Darge K, Kooijman H, Troeger J. Combined static-dynamic MR urography for the simultaneous evaluation of morphology and function in urinary tract obstruction. II. Findings in experimen-tally induced ureteric stenosis. Pediatr Radiol 2000;30(8):523-32.

12. Schwarzbach M, Dimitrakopoulou­-Strauss A, Willeke F, Hinz U, Strauss LG, Zhang YM, Mechtersheimer G, Attigah N, Lehnert T, Herfarth C. Clinical value of (18­F) Fluordeoxyglucose Positron Emission Tomography imaging in soft tissue sarcomas. Ann Surg 2000;231(3):380-­386.

13. Strauss LG (review). Sensitivity and specificity of positron emission tomography (PET) for the diagnosis of lymph node metastases. Recent Results Cancer Res 2000;157:12-19.

14. Wodarski C, Eisenbarth J, Weber K, Henze M, Haberkorn U, Eisenhut M. Synthesis of 3'-deoxy-3'-[18F]fluoro-thymidine with 2,3´-O-anhydro-5´-O-(4,4´-dimethoxytrityl) thymidine. J Labeled Compd Radiopharm 2000;43:1211-1218.


1. Haberkorn U. Monitoring of gene therapy with PET. In; pp PET in clinical oncology. Wieler HJ, Coleman RE (ed.) Darmstadt 2000; pp 397-410.

2. Haberkorn U. Nuclear medicine and the monitoring of gene therapy. In: Molecular nuclear medicine with antibodies, peptides and nucleotides. Munz DL (ed.) Zuckschwerdt München 2000; pp 50-65.

nach oben